Ameena El-Bibany

We are advancing small molecule therapeutics for age-related diseases. Our platform enables precise, dynamic control of biological targets and pathways, generating high-fidelity datasets that, combined with advanced AI, unlock systematic exploration of previously inaccessible chemical space. At its core are our ultra-large, in-house aging datasets, which provide a rich foundation for target identification and therapeutic discovery.

Edison Scientific is building the AI platform for scientific research and development. Kosmos, our AI scientist, collaborates with teams across the full R&D lifecycle, leveraging proprietary data and organizational context to help navigate complex scientific decisions and accelerate timelines from discovery to FDA approval. We believe the full gains from AI in science will only be realized when AI systems are integrated across the entire research and development stack, continuously learning from the evolving scientific context inside an organization. With Edison Scientific, scientists and researchers remain at the center of scientific progress, using AI to amplify their expertise and accelerate discovery at unprecedented speed. Edison is a scientist-led company that was spun out of the nonprofit research lab FutureHouse in 2025, backed by $70M from Spark Capital, Triatomic Capital, Susa Ventures, Pillar Ventures, among other investors.

Portal is building the universal infrastructure for cell engineering across drug discovery and cell therapy. Our proprietary mechanical system enables efficient, scalable delivery of RNA, gene editors, probes, and other molecules into hard-to-transfect cells across many cell types and workflows. With more than 100 customer sites including the top 10 pharma, researchers use Portal to run high-throughput, physiologically relevant screens and de-risk targets earlier, while cell therapy developers leverage the platform to multi-engineer cells beyond the limits of viral or electroporation methods. Integrated with leading high-throughput robotics and with GMP manufacturing systems, Portal is powering both next-generation discovery and laying the groundwork for future point-of-care cell therapy manufacturing.

Unlocking translational proteomics for the next stage of human health

Biological Software is one or more synthetic molecules that execute complex functions, specified from a program, in a biological system. We are creating tools to develop increasingly powerful biological software for the rational design of novel, broadly accessible medicines and biotechnologies previously out of reach. Our antedisciplinary team of scientists, machine learning researchers, engineers and entrepreneurs is growing. If you are excited to learn, teach, discover, and create together in pursuit of learning lifes languages to improve the lives of billions of people around the world, please visit our website.

At Activ Surgical, our mission is for every surgical imaging system to deliver intelligent information that reduces surgical complication rates, ushering in a new standard of patient care and safety. Having completed the world’s first autonomous robotic surgery of soft tissue in 2018, the company is focused on enhanced, real-time visualization capabilities for surgeons that combine advanced augmented reality (AR), artificial intelligence (AI), and machine learning (ML) technology. Our vision is to transform the collective surgical experience by leveraging emerging technologies and data into insights that make world-class surgery accessible for all.

Aspect Biosystems is a biotechnology company pioneering the development of a novel category of cellular medicines designed to replace or restore biological function and deliver curative therapies for some of the most elusive diseases. Aspect is developing these bioengineered cellular medicines by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, therapeutic cells, hypoimmune cell engineering, and advanced biomaterials. Aspect is advancing its therapeutic pipeline across multiple endocrine and metabolic diseases, including diabetes and rare endocrine disorders.

We are advancing small molecule therapeutics for age-related diseases. Our platform enables precise, dynamic control of biological targets and pathways, generating high-fidelity datasets that, combined with advanced AI, unlock systematic exploration of previously inaccessible chemical space. At its core are our ultra-large, in-house aging datasets, which provide a rich foundation for target identification and therapeutic discovery.

Edison Scientific is building the AI platform for scientific research and development. Kosmos, our AI scientist, collaborates with teams across the full R&D lifecycle, leveraging proprietary data and organizational context to help navigate complex scientific decisions and accelerate timelines from discovery to FDA approval. We believe the full gains from AI in science will only be realized when AI systems are integrated across the entire research and development stack, continuously learning from the evolving scientific context inside an organization. With Edison Scientific, scientists and researchers remain at the center of scientific progress, using AI to amplify their expertise and accelerate discovery at unprecedented speed. Edison is a scientist-led company that was spun out of the nonprofit research lab FutureHouse in 2025, backed by $70M from Spark Capital, Triatomic Capital, Susa Ventures, Pillar Ventures, among other investors.

Portal is building the universal infrastructure for cell engineering across drug discovery and cell therapy. Our proprietary mechanical system enables efficient, scalable delivery of RNA, gene editors, probes, and other molecules into hard-to-transfect cells across many cell types and workflows. With more than 100 customer sites including the top 10 pharma, researchers use Portal to run high-throughput, physiologically relevant screens and de-risk targets earlier, while cell therapy developers leverage the platform to multi-engineer cells beyond the limits of viral or electroporation methods. Integrated with leading high-throughput robotics and with GMP manufacturing systems, Portal is powering both next-generation discovery and laying the groundwork for future point-of-care cell therapy manufacturing.

Page One Ventures is an early-stage venture firm centered in Silicon Valley. We leverage deep partnerships with a global network of iconic institutions and patient capital to create strategic advantages for the companies we work with. We invest in software transforming existing markets and deep technology creating new markets. We believe the rise of technology companies is still at its inception and believe that the future will be written in code and in codons. We focus invest early to align with the exceptional founders. Through previous funds our Partners have invested in 50+ companies who have since raised over $1.5B in follow on financing and have grown to a collective enterprise value of $20B+.

Unlocking translational proteomics for the next stage of human health